Yıl: 2016 Cilt: 27 Sayı: 5 Sayfa Aralığı: 408 - 414 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease

Öz:
Background/Aims: Studies on the therapeutic efficacy of proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD) have been recently published. In most of these studies, comparison of only two PPIs have been made. There are few studies on the comparison of four or more PPIs. We aimed to compare the acid inhibitory effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on days 1 and 5 of treatment in patients with GERD, who were extensive metabolizers in regard to the CYP2C19 genotype.Materials and Methods: Helicobacter pylori-negative with typical symptoms of GERD patients were randomly divided into four treatment groups. Efficacy analysis on days 1 and 5 were performed on the four groups which comprised 10 (esomeprazole), 11 (rabeprazole), 10 (lansoprazole), and 10 (pantoprazole) patients. Results: On day 1 of PPI treatment, the mean percentage of time with intragastric pH>4 were 54%, 58%, 60%, and 35% for the groups, respectively, and on day 5, these values were 67%, 60%, 68%, and 59%, respectively. Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment.Conclusion: Pantoprazole is a less potent proton pump inhibitor than the other PPIs tested on the first day of treatment. When the time needed to raise the intragatric pH to over 4 was evaluated, esomeprazole was found to have the most rapid action, followed by lansoprazole and rabeprazole
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Joelsson B, Johnsson F. Heartburn--the acid test. Gut 1989; 30: 1523-5. [CrossRef ]
  • 2. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and Clinical Spectrum of Gastroesophageal Reflux: A Population-Based Study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56. [CrossRef ]
  • 3. Bor S, Mandiracioglu A, Kitapcioglu G, Caymaz-Bor C, Gilbert RJ. Gastroesophageal reflux in a low-income region in Turkey. Am J Gastroenterol 2005; 100: 744-54. [CrossRef ]
  • 4. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management—the Genval workshop report. Gut 1999; 44(Suppl 2): S1-16.
  • 5. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and the management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108: 308-28. [CrossRef ]
  • 6. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64: 935-51. [CrossRef ]
  • 7. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24. [CrossRef ]
  • 8. Dickson EJ, Stuart RC. Genetics of response to proton pump inhibitor therapy. Am J Pharmacogenomics 2003; 3: 303-15. [CrossRef ]
  • 9. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58. [CrossRef ]
  • 10. Celebi A, Kocaman O, Savlı H, Konduk BT, Senturk O, Hulagu S. The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. Turk J Gastroenterol 2009; 20: 161-4. [CrossRef ]
  • 11. Tolman KG, Täubel J, Warrington S, Chiu YL, Pimler BL, Pan WJ. Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragas- 413 tric pH in healthy volunteers. Clin Drug Investig 2006; 26: 21-8. [CrossRef ]
  • 12. Röhss K, Wilder-Smith C, Kilhamn J, Fjellman, Lind T. Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 345-54. [CrossRef ]
  • 13. Hartmann D, Eickhoff A, Damian U, Riemann JF, Schilling D. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. Eur J Gastroenterol Hepatol 2007; 19: 133-7. [CrossRef ]
  • 14. Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily–a randomized, two-way crossover study. Aliment Pharmacol Ther 2005; 21: 963-7. [CrossRef ]
  • 15. Johnson DA, Stacy T, Ryan M, et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22: 129-34. [CrossRef ]
  • 16. Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2007; 25: 501-10. [CrossRef ]
  • 17. Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur J Clin Pharmacol 2006; 62: 685-91. [CrossRef ]
  • 18. Li ZS, Zhan XB, Xu GM, Cheng NN, Liao Z. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial. J Gastroenterol Hepatol 2007; 22: 815- 20. [CrossRef ]
  • 19. Röhss K, Lind T, Wilder-Smith C. Esomeprazol 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60: 531-9. [CrossRef ]
  • 20. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-14. [CrossRef ]
  • 21. Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20. [CrossRef ]
  • 22. Wilder-Smith C, Lind T, Lundin C, Naucler E, Nilsson-Pieschl C, Röhss K. Acid control with esomeprazole and lansoprazole: A comparative dose-response study. Scand J Gastroenterol 2007; 42: 157-64. [CrossRef ]
  • 23. Hunfeld NG, Touw DJ, Mathot RA, Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2012; 35: 810-8. [CrossRef ]
  • 24. Sugimoto M, Shirai N, Nishino M, et al. Comparison of acid inhibition with standart dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol 2014; 70: 1073-8. [CrossRef ]
  • 25. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-91. [CrossRef ]
  • 26. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors. Drugs 2003; 63: 2739-54. [CrossRef ]
  • 27. Hunfeld NG, Touw DJ, Mathot RA, et al. A comparison of the acidinhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2010; 31: 150-9. [CrossRef ]
APA ÇELEBİ A, AYDIN D, KOCAMAN O, KONDUK B, Senturk O, HÜLAGÜ S (2016). Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. , 408 - 414.
Chicago ÇELEBİ Altay,AYDIN Dincer,KOCAMAN Orhan,KONDUK BUĞRA TOLGA,Senturk Omer,HÜLAGÜ Sadetin Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. (2016): 408 - 414.
MLA ÇELEBİ Altay,AYDIN Dincer,KOCAMAN Orhan,KONDUK BUĞRA TOLGA,Senturk Omer,HÜLAGÜ Sadetin Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. , 2016, ss.408 - 414.
AMA ÇELEBİ A,AYDIN D,KOCAMAN O,KONDUK B,Senturk O,HÜLAGÜ S Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. . 2016; 408 - 414.
Vancouver ÇELEBİ A,AYDIN D,KOCAMAN O,KONDUK B,Senturk O,HÜLAGÜ S Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. . 2016; 408 - 414.
IEEE ÇELEBİ A,AYDIN D,KOCAMAN O,KONDUK B,Senturk O,HÜLAGÜ S "Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease." , ss.408 - 414, 2016.
ISNAD ÇELEBİ, Altay vd. "Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease". (2016), 408-414.
APA ÇELEBİ A, AYDIN D, KOCAMAN O, KONDUK B, Senturk O, HÜLAGÜ S (2016). Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turkish Journal of Gastroenterology, 27(5), 408 - 414.
Chicago ÇELEBİ Altay,AYDIN Dincer,KOCAMAN Orhan,KONDUK BUĞRA TOLGA,Senturk Omer,HÜLAGÜ Sadetin Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turkish Journal of Gastroenterology 27, no.5 (2016): 408 - 414.
MLA ÇELEBİ Altay,AYDIN Dincer,KOCAMAN Orhan,KONDUK BUĞRA TOLGA,Senturk Omer,HÜLAGÜ Sadetin Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turkish Journal of Gastroenterology, vol.27, no.5, 2016, ss.408 - 414.
AMA ÇELEBİ A,AYDIN D,KOCAMAN O,KONDUK B,Senturk O,HÜLAGÜ S Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turkish Journal of Gastroenterology. 2016; 27(5): 408 - 414.
Vancouver ÇELEBİ A,AYDIN D,KOCAMAN O,KONDUK B,Senturk O,HÜLAGÜ S Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turkish Journal of Gastroenterology. 2016; 27(5): 408 - 414.
IEEE ÇELEBİ A,AYDIN D,KOCAMAN O,KONDUK B,Senturk O,HÜLAGÜ S "Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease." Turkish Journal of Gastroenterology, 27, ss.408 - 414, 2016.
ISNAD ÇELEBİ, Altay vd. "Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease". Turkish Journal of Gastroenterology 27/5 (2016), 408-414.